Tumour hypoxia induces a metabolic shift causing acidosis: a common feature in cancer, J. Cell Mol. Med, vol.14, pp.771-794, 2010. ,
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics, Oncogene, vol.29, pp.625-634, 2010. ,
, Semin. Canc. Biol, vol.35, pp.276-304, 2015.
The reaction of platinum(II) complexes with DNA. Kinetics of intrastrand crosslink formation in vitro, Nucleic Acids Res, vol.19, pp.1483-1489, 1991. ,
Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis, Cell Death Differ, vol.14, issue.12, 2007. ,
Complex regulation of p73 isoforms after alteration of amyloid precursor polypeptide (APP) function and DNA damage in neurons, J. Biol. Chem, vol.286, pp.43013-43025, 2011. ,
Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches, Curr. Med. Chem, vol.12, pp.2075-2094, 2005. ,
New trends for metal complexes with anticancer activity, Curr. Opin. Chem. Biol, vol.12, pp.197-206, 2008. ,
Antitumour metal compounds: more than theme and variations, Dalton Trans, pp.183-194, 2008. ,
Toxicities of the platinum antineoplastic agents, Expet Opin. Drug Saf, vol.2, pp.597-607, 2003. ,
The resurgence of platinum-based cancer chemotherapy, Nat. Rev. Canc, vol.7, pp.573-584, 2007. ,
Ruthenium in medicine: current clinical uses and future prospects, Platin. Met. Rev, vol.45, p.62, 2001. ,
Metal-based antitumour drugs in the post genomic era, Dalton Trans, pp.1929-1933, 2006. ,
Synthesis and antitumor activity of triazoliumbis(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepentachlororuthenate (III), Arzneimittelforschung, vol.37, pp.770-771, 1987. ,
Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in the Lewis lung carcinoma system, Pharmacol. Res, vol.21, pp.617-628, 1989. ,
New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells, Cancer Res, vol.51, pp.2943-2948, 1991. ,
Inhibition of cancer cell growth by ruthenium(II) arene complexes, J. Med. Chem, vol.44, pp.3616-3621, 2001. ,
Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates, J. Inorg. Biochem, vol.106, pp.90-99, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02360300
Tris(tetramethylphenanthroline)ruthenium(II): a chiral probe that cleaves A-DNA conformations, Proc. Natl. Acad. Sci. U. S. A, vol.85, pp.1339-1343, 1988. ,
DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair, Prog. Nucleic Acid Res. Mol. Biol, vol.71, pp.1-68, 2002. ,
Ruthenium (II)-derived organometallic compounds induce cytostatic and cytotoxic effects on mammalian cancer cell lines through p53-dependent and p53-independent mechanisms, J. Pharmacol. Exp. Therapeut, vol.315, pp.1403-1411, 2005. ,
URL : https://hal.archives-ouvertes.fr/inserm-02360373
Investigation of the role of Bax, p21/Waf1 and p53 as determinants of cellular responses in HCT116 colorectal cancer cells exposed to the novel cytotoxic ruthenium(II) organometallic agent, RM175, Cancer Chemother. Pharmacol, vol.55, pp.577-583, 2005. ,
The ruthenium(II)-arene compound RAPTA-C induces apoptosis in EAC cells through mitochondrial and p53-JNK pathways, J. Biol. Inorg. Chem, vol.13, pp.1149-1155, 2008. ,
DNA binding to an anticancer organo-ruthenium complex, J. Phys. Chem. B, vol.114, pp.14041-14047, 2010. ,
A ruthenium-containing organometallic compound reduces tumor growth through induction of the endoplasmic reticulum stress gene CHOP, Cancer Res, vol.69, issue.13, pp.5458-5466, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-02360367
Induction of caspase 8 and reactive oxygen species by ruthenium-derived anticancer compounds with improved water solubility and cytotoxicity, Biochem. Pharmacol, vol.84, pp.1428-1436, 2012. ,
New synthesis and new bio-application of cyclometalated ruthenium(II) complexes for fast mediated electron transfer with peroxidase and glucose oxidase, Inorg. Chem, vol.40, pp.6529-6532, 2001. ,
Library of second-generation cycloruthenated compounds and evaluation of their biological properties as potential anticancer drugs: passing the nanomolar barrier, Dalton Trans, vol.40, pp.8869-8878, 2011. ,
Impact of cyclometalated ruthenium(II) complexes on lactate dehydrogenase activity and cytotoxicity in gastric and colon cancer cells, J. Inorg. Biochem, vol.163, pp.28-38, 2016. ,
Competition between glutathione and guanine for a ruthenium(II) arene anticancer complex: detection of a sulfenato intermediate, J. Am. Chem. Soc, vol.127, pp.17734-17743, 2005. ,
Redox-active antineoplastic ruthenium complexes with indazole: correlation of in vitro potency and reduction potential, J. Med. Chem, vol.48, pp.2831-2837, 2005. ,
A ruthenium anticancer compound interacts with histones and impacts differently on epigenetic and death pathways compared to cisplatin, Oncotarget, vol.8, issue.2, pp.2568-2584, 2017. ,
The tissue-specific transcription factor Pit-1/ GHF-1 binds to the c-fos serum response element and activates c-fos transcription, Mol. Endocrinol, vol.13, pp.742-751, 1999. ,
Transcriptional effects in GH3 cells of Gs alpha mutants associated with human pituitary tumors: stimulation of adenosine 3',5'-monophosphate response element-binding protein-mediated transcription and of prolactin and growth hormone promoter activity via protein kinase A, Endocrinology, vol.136, pp.4331-4338, 1995. ,
Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization, Cancer Res, vol.74, pp.3535-3545, 2014. ,
SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions, Biochim. Biophys. Acta, vol.1804, pp.1666-1675, 2010. ,
, Hypoxia-inducible factor-1 (HIF-1), vol.70, pp.1469-1480, 2006.
Hypoxia signalling through mTOR and the unfolded protein response in cancer, Nat. Rev. Canc, vol.8, pp.851-864, 2008. ,
Activation of the HIF prolyl hydroxylase by the iron chaperones PCBP1 and PCBP2, Cell Metabol, vol.14, pp.647-657, 2011. ,
Synthesis of cycloruthenated compounds as potential anticancer agents, Eur. J. Inorg. Chem, pp.3055-3066, 2007. ,
Angiogenesis and cancer prevention: a vision, Recent Results Canc. Res, vol.174, pp.219-224, 2007. ,
Transition metal chemistry of glucose oxidase, horseradish peroxidase, and related enzymes, Adv. Inorg. Chem, vol.55, pp.201-270, 2004. ,
p53 in survival, death and metabolic health: a lifeguard with a licence to kill, Nat. Rev. Mol. Cell Biol, vol.16, pp.393-405, 2015. ,
Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism, Cancer Lett, vol.373, pp.36-44, 2016. ,
Structural tuning of organoruthenium compounds allows oxidative switch to control ER stress pathways and bypass multidrug resistance, Chem. Sci, vol.7, pp.4117-4124, 2016. ,
Hypoxia-induced endoplasmic reticulum stress characterizes a necrotic phenotype of pancreatic cancer, Oncotarget, vol.6, pp.32154-32160, 2015. ,
Glucose deprivation induces reticulum stress by the PERK pathway and caspase-7-and calpain-mediated caspase-12 activation, Apoptosis: Int. J. Program. Cell Death, vol.19, pp.414-427, 2014. ,
A liaison between mTOR signaling, ribosome biogenesis and cancer, Biochim. Biophys. Acta, vol.1849, pp.812-820, 2015. ,
Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling, Trends Cell Biol, vol.22, pp.274-282, 2012. ,